

sanofi

•

Immunology Investor Event


Epidemiology

Cambridge, MA

•

March 29, 2022


Dupixent: Atopic Dermatitis Adult 18+



Source: Sanofi analysis

(1) Germany, France, Italy, Spain & United Kingdom. (2) For EU, patients who have inadequate response or intolerant to immunosuppressants


Dupixent: Atopic Dermatitis Adolescents 12-17yo



Source: Sanofi analysis


(1) Germany, France, Italy, Spain & United Kingdom. (2) For Europe, patients who have inadequate response or intolerant to immunosuppressants

Dupixent: Atopic Dermatitis Child 6-11yo




Source: Sanofi analysis
 (1) Germany, France, Italy, Spain & United Kingdom.

Dupixent: Atopic Dermatitis Child <6yo



Source: Sanofi analysis
 (1) Germany, France, Italy, Spain & United Kingdom.

Dupixent: Asthma 12+




Source: Sanofi analysis

ICS: Inhaled Corticosteroids; OCS: Oral Corticosteroids

(1) Germany, France, Italy, Spain & United Kingdom (2) For Europe, severe with persistent use of ICS or OCS. (3) For EU, severe uncontrolled or OCS dependent


Dupixent: Asthma 6-11yo



Source: Sanofi analysis
 ICS: Inhaled Corticosteroids; OCS: Oral Corticosteroids
 (1) Germany, France, Italy, Spain & United Kingdom (2) For Europe, severe uncontrolled type 2

Dupixent: Chronic Obstructive Pulmonary Disease

Number of patients (thousands)




Source: Sanofi analysis

SoC: Standard of Care; GOLD criteria: Global Initiative for Chronic Obstructive Lung Disease - Group D: high risk (≥2 exacerbations / year, or one+ requiring hospitalization) and more symptoms (mMRC≥ 2 or CAT≥ 10)

(1) Germany, France, Italy, Spain & United Kingdom

Dupixent: Chronic Rhinosinusitis with Nasal Polyposis




Source: Sanofi analysis

(1) 18+ population (2) Germany, France, Italy, Spain & United Kingdom


(3) For Europe, patients with severe CRSwNP inadequately controlled on systemic corticosteroids and / or surgery

Dupixent: Chronic Rhinosinusitis Sans Nasal Polyposis




Source: Sanofi analysis
(1) 12+ population

Dupixent: AFRS




Source: Sanofi analysis
(1) 12+ population

Dupixent: Bullous Pemphigoid



Source: Sanofi analysis
 OCS: Oral Corticosteroids
 (1) 18+ population
 (2) Germany, France, Italy, Spain & United Kingdom

Dupixent: Prurigo Nodularis




Source: Sanofi analysis

(1) 18+ population


(2) Germany, France, Italy, Spain & United Kingdom

Dupixent: Chronic Spontaneous Urticaria




Source: Sanofi analysis
 (1) 12+ population

Dupixent: Chronic Inducible Urticaria (Cold)




Source: Sanofi analysis
 (1) 12+ population

Dupixent: Chronic Pruritis of Unknown Origin



Source: Sanofi analysis
 (1) 18+ population

Dupixent: Eosinophilic Esophagitis 12+



Source: Sanofi analysis
 PPI = Proton pump inhibitor
 (1) Germany, France, Italy, Spain & United Kingdom